The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes

AIMS: To investigate whether the proven benefits of insulin degludec (IDeg) combined with insulin aspart (IAsp), known as IDegAsp, given twice daily, extend across a wide spectrum of patients with diabetes. MATERIALS AND METHODS: This was a post hoc pooled analysis of 5 phase III randomized, 26‐week...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Diabetes Obes Metab
Auteurs principaux: Haluzík, Martin, Fulcher, Greg, Pieber, Thomas R., Bardtrum, Lars, Tutkunkardas, Deniz, Rodbard, Helena W.
Format: Artigo
Langue:Inglês
Publié: Blackwell Publishing Ltd 2018
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033009/
https://ncbi.nlm.nih.gov/pubmed/29451706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13261
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires